White House claims success in tackling prescription drug shortage

Congress now needs to step up and make FDA notification of potential shortages mandatory in more cases. Bipartisan legislation championed by Reps. Tom Rooney (R-Fla.) and Diana DeGette (D-Colo.) and by Sens. Amy KlobucharAmy KlobucharCruz: Jokes about me in Franken's book 'obnoxious' The Hill's 12:30 Report Dem senators accuse Trump of purposefully holding back information MORE (D-Minn.) and Susan CollinsSusan CollinsSenate takes lead on Trump’s infrastructure proposal Navy leaders defend Trump's lackluster ship budget Overnight Healthcare: CBO fallout | GOP senators distance themselves from House bill | Trump budget chief blasts score | Schumer says House bill belongs 'in the trash' MORE (R-Maine) has lingered in both chambers.

DeParle goes on to detail actions the agency has taken to preserve access to two cancer drugs: 

"To avert an impending shortage of methotrexate, a drug used to treat children with leukemia, the FDA has worked with manufacturers to help ramp up production and has approved a new application to produce the version of the drug that is most needed, which will further bolster supply and ensure patients have access to this lifesaving medicine. 

"To end the shortage of the cancer drug Doxil, the FDA will allow the temporary importation of a replacement drug. This action should address patient needs and end this drug shortage."

In addition, the agency released draft guidance Tuesday regarding mandatory and voluntary notification to FDA of issues that could result in a drug shortage.

"Today's announcement shows that we're making a difference and protecting the health of the American people," DeParle wrote. "And we'll continue our aggressive efforts to prevent drug shortages and ensure patients get the medicines they need."